



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Finklestein, S. et al.

Application No: 10/605,456

Filed: September 30, 2003

For: *Promoting Recovery from Damage to
the Central Nervous System*

Examiner: Not Yet Assigned

Art Unit: 1632

Confirmation No.: 2455

Attorney Document No. CBA-003.02

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on January 6, 2004.


Shirine Darvish

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)(3)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The above-referenced application is a continuation of USSN 09/642,277, which was filed on August 18, 2000. Accordingly, Applicants request that all documents made of record in USSN 09/642,277 be made of record in the above-referenced application. Copies are submitted herewith of Forms PTO 1449 filed May 14, 2001 and January 10, 2003.

In accordance with 37 CFR 1.98(d)(2), no copies of the references cited in these Forms PTO 1449 are enclosed herewith, because the Information Disclosure Statements filed in USSN 09/642,277 complied with 37 CFR 1.98 sections (a) through (c).

In addition, a further Form PTO/SB/08a is filed listing references cited by the Examiner in USSN 09/642,277. Copies of the documents are not submitted because they were all made of record in USSN 09/642,277.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form PTO/SB/08a.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that the listed documents are material or constitute "prior art." If the Examiner applies the cited documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of said document. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the cited references be applied against the claims of the present application.

This Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits; therefore, no fees are due. However, the Commissioner is authorized to credit any overpayment or charge any deficiencies to/from our Deposit Account, No. 06-1448.

Respectfully submitted,
FOLEY HOAG LLP

By: 

Scott E. Kamholz
Reg. No. 48,543
Agent for Applicants

Date: January 6, 2004
Customer No.: 25181
Patent Group
Foley Hoag LLP
155 Seaport Blvd
Boston MA 02210-2600
Voice: (617) 832-1230



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

<i>Application Number</i>	10/605,456
<i>Filing Date</i>	September 30, 2003
<i>First Named Inventor</i>	Finklestein, Seth
<i>Art Unit</i>	1632
<i>Examiner Name</i>	Not Yet Known
<i>Attorney Docket Number</i>	CBA-003.02

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	N	FR 2 642 086	07-1990	Caput et al.		
	O	WO 00/71715	11-2000	Rosen et al.		
	P	EP 86117257.5	06-1987	Moscatelli et al.		
	Q	EP 89101162.9	08/1989	Senoo et al.		


**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/605,456
				Filing Date	September 30, 2003
				First Named Inventor	Finkelstein, Seth
				Art Unit	1632
				Examiner Name	Not Yet Known
Sheet	2	of	2	Attorney Docket Number	CBA-003.02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	U	Barker et al., Neural transplantation therapies for Parkinson's and Huntington's Diseases, 2001, DDT, Vol. 6 pp. 575-582	
	V	Kmiec, Investigators have been searching for ways to add corrective genes to cells harboring defective genes..., 1999, AMERICAN SCIENTIST, Vol. 87, pp. 240-247	
	W	Daughaday et al., Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations, 1989, ENDOCRINE REVIEWS, Vol. 10, pp. 68-91	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)

 Docket Number (Optional)
CBA-003.01

 Application Number
09/642,277

 Applicant
Finklestein et al.

 Filing Date
August 18, 2000

 Group Art Unit
1645 1636

MAY 17 2001

JAN 09 2004

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SSP	AA 5,175,103	Dec. 29, 1992	Lee et al.	435	172.3	Oct. 21, 1991
	AB 5,270,191	Dec 14, 1993	McKay et al.	435	172.3	May 12, 1992
	AC 5,733,871	March 31, 1998	Alps et al.	514	12	March 16, 1995
	AD 5,750,376	May 12, 1998	Weiss et al.	435	69.52	June 7, 1995
	AE 5,753,506	May 19, 1998	Johe	435	377	September 25, 1996
	AF 5,840,580	November 24, 1998	Terstappen et al.	435	372	May 14, 1997
	AG 5,914,108	June 22, 1999	Tsukamoto et al.	424	93.7	June 6, 1995
	AH 5,958,767	Sep. 28, 1999	Snyder et al.	435	368	Aug. 14, 1998
	AI 5,968,829	October 19, 1999	Carpenter	435	467	September 5, 1997

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
SSP	AJ WO 94/03199	17 February 1994	PCT				
	AK WO 95/24469	14 September 1995	PCT				
	AL WO 96/15224	23 May 1996	PCT				
	AM WO 00/00588	6 January 2000	PCT				

RECEIVED

MAY 21 2001

TECH CENTER 1600/2900

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

SSP	AN	Aebischer, P. et al., "Transplantation of Polymer Encapsulated Neurotransmitter Secreting Cells: Effect of the Encapsulation Technique", Journal of Biomechanical Engineering 113: 178-183 (May 1991).
	AO	Andersson, Candace et al., "Transplantation of Cultured Type 1 Astrocyte Cell Suspensions into Young, Adult and Aged Rat cortex: Cell Migration and Survival", Int. J. Devl. Neuroscience 11(5): 555-568 (1993).
	AP	Andsberg, Gunner ET al., "Amelioration of Ischaemia-Induced Neuronal Death in the Rat Striatum by NGF-Secreting Neural Stem Cells", European Journal of Neuroscience 10: 2026-2036 (1998).
	AQ	Bavetta, Seb et al., "The Effects of FK506 on Dorsal Column Axons Following Spinal Cord Injury in Adult Rats: Neuroprotection and Local Regeneration", Experimental Neurology 158: 382-393 (1999).
	AR	Bhatia, Mickie et al., "A Newly Discovered Class of Human Hematopoietic Cells with SCID-Repopulating Activity", Nature Medicine 4(9): 1038-1045 (September 1998).

Examiner: Sita Pappu

Date: 05/08/02

Form PTO-1449		Docket Number (Optional) CBA-003.01		Application Number 09/642,277	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		Applicant Finklestein et al.		Group Art Unit 4645-1636	
		Filing Date August 18, 2000			
SSP	AS	Chen, J. MD, et al., "Intracerebral Transplantation of Bone Marrow with BDNF after MCAo in Rat", Neuropharmacology 39: 711-716 (2000)			
	AT	Lopez-Coviella, Ignacio et al., "Induction and Maintenance of the Neuronal Cholinergic Phenotype in the Central Nervous System by BMP-9", Science 289: 313-316 (14 July 2000).			
MAY 21 2001 RECEIVED	AU	Cramer, Steven C., MD et al., "A Functional MRI Study of Subjects Recovered from Hemiparetic Stroke", Stroke 28: 2518-2527 (199&).			
	AV	Eglitis, Martin A. et al., "Hematopoietic Cells Differentiate into Both Microglia and Macrogia in the Brains of Adult Mice", Proc. Natl. Acad. Sci. USA 94: 4080-4085 (April 1997).			
	AW	Evans, M.J. et al., "Establishment in Culture of Pluripotential Cells from Mouse Embryos", Nature 292: 154-156 (9 July 1981).			
	AX	Fisher, Marc et al., "Delayed Treatment with Intravenous Basic Fibroblast Growth Factor Reduces Infarct Size Following Permanent Focal Cerebral Ischemia in Rats", Journal of Cerebral Blood Flow and Metabolism 15: 953-959 (1995).			
	AY	Flax, Jonathan D. et al., "Engraftable Human Neural Stem Cells Respond to Developmental Cues, Replace Neurons, and Express Foreign Genes", Nature Biotechnology 16(11): 1033-1039 (November 1998).			
	AZ	Gage, Fred H., "Survival and Differentiation of Adult Neuronal Progenitor Cells Transplanted to the Adult Brain", Proc. Natl. Acad. Sci. USA 92: 11879-11883 (December 1995).			
	BA	Griffith, Diana L. et al., "Three-Dimensional Structure of Recombinant Human Osteogenic Protein 1: Structural Paradigm for the Transforming Growth Factor β Superfamily", Proc. Natl. Acad. Sci. USA 93: 878-883 (January 1996).			
	BB	Jones, Theresa A. et al., "Use-Dependant Growth of Pyramidal Neurons after Neocortical Damage", Journal of Neuroscience 14(4): 2140-2152 (April 1994).			
	BC	Kawamata, Takakazu et al., "Intracisternal Antisense Oligonucleotide to Growth Associated Protein-43 Blocks the Recovery-Promoting Effects of Basic Fibroblast Growth Factor after Focal Stroke", Experimental Neurology 158: 89-96 (1999).			
	BD	Kawamata, Takakazu et al., "Intracisternal Basic Fibroblast Growth Factor (bFGF) Enhances Behavioral Recovery Following Focal Cerebral Infarction in the Rat", Journal of Cerebral Blood Flow and Metabolism 16: 542-547 (1996).			
	BE	Kawamata, Takakazu et al., "Intracisternal Basic Fibroblast Growth Factor Enhances Functional Recovery and Up-Regulates the Expression of a Molecular Marker of Neuronal Sprouting Following Focal Cerebral Infarction", Proc. Natl. Acad. Sci. USA 94: 8179-8184 (July 1997).			
	BF	Kuhn, H. Georg et al., "Epidermal Growth Factor and Fibroblast Growth Factor-2 Have Different Effects on Neural Progenitors in the Adult Rat Brain", Journal of Neuroscience 17(15): 5820-5829 (August 1, 1997).			
	BG	Ling, Zao Dung et al., "Differentiation of Mesencephalic Progenitor Cells into Dopaminergic Neurons by Cytokines", Experimental Neurology 149: 411-423 (1998).			
	BH	Lobsiger, Christian S. et al., "Platelet-Derived Growth Factor-BB Supports the Survival of Cultured Rat Schwann Cell Precursors in Synergy with Neurotrophin-3" GLIA 30: 290-300 (2000).			
✓	BI	Martin, Gail R., "Isolation of a Pluripotent Cell Line from Early Mouse Embryos Cultured in Medium Conditioned by Teratocarcinoma Stem Cells", Proc. Natl. Acad. Sci. USA 78(12): 7634-7638 (December 1981).			

Form PTO-1449

**INFORMATION DISCLOSURE REPORT
IN AN APPLICATION**
(Use several sheets if necessary)

Docket Number (Optional)

CBA-003.01

Application Number

09/642,277

Applicant

Finklestein et al.

JAN 09 2004

Filing Date

August 18, 2000

Group Art Unit

1645-1636

Mehler, Mark F. et al., "Cytokine Regulation of Neuronal Differentiation of Hippocampal Progenitor Cells", Nature 362: 62-64 (4 March 1993).

Miraglia, Sheri et al., "A Novel Five-Transmembrane Hematopoietic Stem Cell Antigen: Isolation, Characterization and Molecular Cloning", Blood 90(12): 5013-5021 (December 15, 1997).

Park, Kook In et al., "Transplantation of Neural Progenitor and Stem Cells: Developmental Insights May Suggest New Therapies for Spinal Cord and Other CNS Dysfunction" Journal of Neurotrauma 16(8): 675-687 (1999).

Ray, Jasodhara et al., "A 10-Amino Acid Sequence of Fibroblast Growth Factor 2 is Sufficient for its Mitogenic Activity on Neural Progenitor Cells", Proc. Natl. Acad. Sci. USA 94: 7047-7052 (June 1997).

Ren, JingMei, et al., "Time Window of Intracisternal Osteogenic Protein-1 in Enhancing Functional Recovery after Stroke", Neuropharmacology 39: 860-865 (2000).

Snyder, Evan Y. et al., "Multipotent Neural Precursors can Differentiate Toward Replacement of Neurons Undergoing Targeted Apoptotic Degeneration in Adult Mouse Neocortex", Proc. Natl. Acad. Sci. USA 94: 11663-11668 (October 1997).

Stroemer, R. Paul PhD et al., "Enhanced Neocortical Neural Sprouting, Synaptogenesis, and Behavioral Recovery with D-Amphetamine Therapy after Neocortical Infarction in Rats", Stroke 29: 2381-2395 (1998).

Tamura, A. et al., "Focal Cerebral Ischaemia in the Rat: 1. Description of Technique and Early Neuropathological Consequences Following Middle Cerebral Artery Occlusion", Journal of Cerebral Blood Flow and Metabolism 1: 53-60 (1981).

Thomson, James A. et al., "Embryonic Stem Cell Lines Derived from Human Blastocysts", Science 282: 1145-1147 (6 November 1998).

Van Vactor, David et al., "Neural Development: The Semantics of Axon Guidance", Current Biology 9: R201-R204 (1999).

Villa, Ana et al., "Establishment and Properties of a Growth Factor-Dependant, Perpetual Neural Stem Cell Line from the Human CNS", Experimental Neurology 161: 67-84 (2000).

Withers, G. S. et al., "Bone Morphogenetic Protein-7 Enhances Dendritic Growth and Receptivity to Innervation in Cultured Hippocampal Neurons", European Journal of Neuroscience 12: 106-116 (2000).

Yrjanheikki, Juha et al., "Tetracyclines Inhibit Microglial Activation and are Neuroprotective in Global Brain Ischemia", Proc. Natl. Acad. Sci. USA 95: 15769-15774 (December 1998).